Trevi Therapeutics Inc（TRVI）财务数据TRVITrevi Therapeutics Inc

Evaluating the bottom line, Trevi Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -19.66%, provide a clear picture of how effectively TRVI converts its operational activities into shareholder value.

In the context of the broader market, TRVI competes directly with industry leaders such as URGN and SEPN. With a market capitalization of $1.82B, it holds a significant position in the sector. When comparing efficiency, TRVI's gross margin of N/A stands against URGN's 90.93% and SEPN's 100.00%. Such benchmarking helps identify whether Trevi Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Trevi has reported consistent losses, with Q2 2026 net income at -$17.8 million and a negative EPS of -0.11. The company's current ratio is strong at 37.28, indicating good liquidity, but it has a negative P/E ratio of -33.76, reflecting ongoing losses.